| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| Alibaba Health (Hong Kong) Technology Company Limited | 0 | 3.28% | — | 6 months |
| Delta Capital Hong Kong Limited | 0 | 1.70% | — | 6 months |
| Jointown International Group Company Limited | 0 | 3.31% | — | 6 months |
| 复星实业(香港)有限公司 | 0 | 5.52% | — | 6 months |
| 和达金源(香港)有限公司 | 0 | 27.31% | — | 6 months |
| 吴启元 | 0 | 3.02% | — | 6 months |
| 香港健友实业有限公司 | 0 | 5.52% | — | 6 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| Top 5 | 54.63% | 27.31% |
| Top 10 | 99.50% | 49.75% |
| Top 25 | 99.92% | 49.96% |
九源基因 IPO attracted overwhelming investor interest, evidenced by an oversubscription ratio of 675.83, one of the highest in recent listings. The data indicates zero accepted applications among 30,759 valid submissions, reflecting an effective zero allocation rate and extreme share scarcity. This fervent demand suggests strong market confidence despite the HK$12.42 offer price. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Allocation patterns show a distinct anomaly: both 甲尾 (last A-tier) at 400,000 shares and 乙头 (first B-tier) at 450,000 shares received only 1 expected lot, neutralizing any tier advantage. This means larger applications with higher broker fees gained no extra benefit, highlighting cost inefficiency especially for those just entering the B-tier. The narrow gap between tiers amplifies this effect. (This is AI-generated commentary based on historical data. Broker fee structures vary and actual costs may differ. Not financial advice.)
Provided demographic data is incomplete, with total holders, mainland China, and Hong Kong participation rates all recorded as zero, likely due to reporting gaps. Typically, high-demand IPOs see significant mainland participation, but no conclusions can be drawn without verified data. Investors should consult official HKEX filings for accurate distribution details. (This is AI-generated commentary based on historical data. Data may contain errors or omissions — verify against official HKEX filings. Not financial advice.)
This page shows allotment analysis for Jiuyuan Gene (02566): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

